English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

CFDA Approves IND for D-Pharm’s Anti-Epileptic Drug in China

Apr. 14, 2015

On April 14th, 2015 D-Pharm Ltd. announced that the Israeli company and its co-development partner Jiangsu Nhwa Pharmaceutical Co., Ltd.  had received an approval letter from the Chinese Food and Drug Administration allowing clinical development through Phase 3 for DP-VPA, an epilepsy treatment drug.

Prior to the IND approval, DP-VPA was granted Fast Track Status, a designation designed to bring important new drugs treating  serious or life-threatening conditions and filling unmet medical needs to patients more quickly.